Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Faron Pharmaceuticals

0.57 EUR

-6.43 %

5,627 following
Corporate customer

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

-6.43 %
-71.54 %
-72.69 %
-73.94 %
-78.07 %
-71.88 %
-85.49 %
-86.64 %
-83.68 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
67.86M EUR
Turnover
682.23K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Reduce
Target price
Updated
10.02.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 10.02.2026

Latest extensive report

Released: 23.08.2022

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
2.3.
2026

Extraordinary general meeting '26

4.3.
2026

Annual report '25

30.3.
2026

General meeting '26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
That new policy stating that two pivotal trials (usually meaning randomized phase 3) might not be necessary if the signal is clear might not change anything for us, i.e., in oncology: ”In practice, many recent drug approvals have already relied on a single pivotal trial—especially...
2 hours ago
by Vino Pino
19
In the article referred to here (New England Journal of Medicine, requires registration), FDA Chief Makary talks about a new policy that will accelerate drug development. It seems that Faron was already aware of this (from Juho’s latest presentation): the upper chart is the FDA’s...
8 hours ago
by Donkey
12
It definitely eases and levels the playing field for these small pharmas’ negotiating positions relative to BP. Right now, many are in a tight spot specifically when it comes to securing funding. At the same time, it creates pressure on the big players to make an offer or partnership...
7 hours ago
by Sperakartio
10
Bexmab study update 2026-02-20 … apparently just study status verified clinicaltrials.gov ClinicalTrials.gov From LinkedIn:
18 hours ago
by Koodinikkari
9
If the rights issue is carried out 1:1 at those 0.6 and 0.5 prices, when the rights are detached, the share price drops to €0.55 and the price of the subscription right becomes €0.05. If you sell the rights, you get €0.05 and there is a 50% dilution. If you sell the shares and subscribe...
20 hours ago
by kallam
8
As a layman, I understand the FDA’s new stance to mean that if, FOR EXAMPLE, Bexmab2 is a complete success, we’ll be straight at the finish line. In practice, things may prove to be more complicated. The “medics” will probably clarify this.
9 hours ago
by Kulkuri
7
Is it too much wishful thinking to hope that the 40m offering Faron is dreaming of would take them straight to the goal and that dealings with Big Pharma would move to a completely new level?
7 hours ago
by Kulkuri
6
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.